Skip to Main Content

Paper Details

The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcoma.
Dev Cell
21
2022
EGFR, O-PDXs, RMS, RMS tumors, Rhabdomyosarcoma, embryonal RMS, myoblasts, paraxial mesoderm population, patient, patients, pediatric cancer, rhabdomyosarcoma, tumor
Author NameAffiliation
Xiang ChenSt. Jude Children's Research Hospital
Xiang ChenSt. Jude Children's Research Hospital
Alberto S PappoSt. Jude Children's Research Hospital
Brent A OrrSt. Jude Children's Research Hospital
Xin ZhouSt. Jude Children's Research Hospital
Xin ZhouSt. Jude Children's Research Hospital
Elizabeth StewartSt. Jude Children's Research Hospital
Elizabeth StewartSt. Jude Children's Research Hospital
  • 1 - 8

Datasets

Release 1.2